Kyowa Hakko Kogyo Licenses Anti-tumor Drug Candidate Mitotic Kinesin Eg5 Inhibitor to Eli Lilly.Tokyo, Japan, Jan 11, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Kyowa Hakko Kogyo announced on January 10 that it has signed a licensing agreement with US pharmaceutical company Eli Lilly Eli Lilly can refer to:
pertaining to mitosis. mitotic activity degree to which a cell population is proliferating; used as an index of tumor aggression. kinesin Eg5 inhibitor, Kyowa Hakko's proprietary compound for anti-tumor agents. Under the agreement terms, Eli Lilly will exclusively develop and market mitotic kinesin Eg5 worldwide except in Japan. Accordingly, Kyowa Hakko Kogyo receives an upfront payment, milestone payments and royalties on sales of commercialized products from Eli Lilly. The compound, which specifically inhibits mitotic kinesin Eg5, arrests the cell division cycle of cancer cells at the mitotic phase and induces apoptosis. Since the compound does not interfere with the formulation of microtubules Microtubules Slender, elongated anatomical channels in worms. Mentioned in: Antihelminthic Drugs , it is expected to develops no serious side effects Side effects Effects of a proposed project on other parts of the firm. such as nerve disorders. Going forward, Eli Lilly will take over the development of mitotic kinesin Eg5 inhibitor and plans to initiate clinical trials in the US and Europe. With this move, the two companies aim to introduce an innovative anti-tumor agent at the earliest date possible. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion